scholarly journals The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Yuya Fujita ◽  
Manabu Kinoshita ◽  
Tomohiko Ozaki ◽  
Koji Takano ◽  
Kei Kunimasa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Genetic Alterations ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
The Impact

Abstract Background Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now play a vital role in patient care of this neoplasm. The authors focused on the impact of epidermal growth factor receptor mutation (EGFR-mt) status on the survival of patients after brain metastases (BMs) from NSCLC. The purpose of the study was to understand the most desirable management of BMs from NSCLC. Methods This was a retrospective observational study analyzing 647 patients with NSCLC, including 266 patients with BMs, diagnosed at our institute between January 2008 and December 2015. EGFR mutation status, overall survival (OS) following diagnosis, OS following BMs, duration from diagnosis to BMs, and other factors related to OS and survival after BMs were measured. Results Among 647 patients, 252 (38.8%) had EGFR mutations. The rate and frequency of developing BMs were higher in EGFR-mt patients compared with EGFR wildtype (EGFR-wt) patients. EGFR-mt patients showed longer median OS (22 vs 11 months, P < .001) and a higher frequency of BMs. Univariate and multivariate analyses revealed that good performance status, presence of EGFR-mt, single BM, and receiving local therapies were significantly associated with favorable prognosis following BM diagnosis. Single metastasis, compared with multiple metastases, exhibited a positive impact on patient survival after BMs in EGFR-mt patients, but not in EGFR-wt NSCLC patients. Conclusions Single BM with EGFR-mt performed better than other groups. Furthermore, effective local therapies were recommended to achieve better outcomes.

scholarly journals Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer

2017 ◽  
Vol 9 (8) ◽  
pp. 2510-2520 ◽  
Author(s):  
Lina Li ◽  
Shuimei Luo ◽  
Heng Lin ◽  
Haitao Yang ◽  
Huijuan Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status

scholarly journals The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel

Oncology ◽  
2020 ◽  
Vol 98 (9) ◽  
pp. 661-668
Author(s):  
Naoki Furuya ◽  
Kentaro Ito ◽  
Tadashi Sakaguchi ◽  
Naoya Hida ◽  
Kazutaka Kakinuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
The Impact

scholarly journals CMET-04. RADIOMICS FEATURES CAN DIFFERENTIATE THE EGFR MUTATION STATUS OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi51-vi51
Author(s):  
Yae Won Park ◽  
Sung Soo Ahn ◽  
Dongmin Choi ◽  
Hwiyoung Kim
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Multiparametric Mri ◽  
Small Cell ◽  
Machine Learning Algorithms ◽  
Small Cell Lung ◽  
Mutation Status

Abstract BACKGROUND AND PURPOSE To assess whether radiomics features on DTI and conventional postcontrast T1-weighted (T1C) images can differentiate the epidermal growth factor receptor (EGFR) molecular status in brain metastases from non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Radiomics features (n = 5046) were extracted from preoperative MRI including T1C and DTI from pathologically confirmed brain metastases of 59 patients with underlying NSCLC and known EGFR mutation status (31 EGFR wild type, 28 EGFR mutant). A subset of 4317 features (85.6%) with high stability (intraclass correlation coefficient > 0.9) were selected for further analysis. After feature selection by the least absolute shrinkage and selection operator, the radiomics classifiers were constructed by various machine learning algorithms. The prediction performance of the classifier was validated by using leave-one-out cross-validation. Diagnostic performance was compared between multiparametric MRI radiomics models and single imaging radiomics models using the area under the curve (AUC) from ROC analysis. RESULTS Thirty-seven significant radiomics features (6 from ADC, 6 from fractional anisotropy [FA], 25 from T1C) were selected. The best performing multiparametric radiomics model (AUC 0.97, 95% CI 0.94–1) showed better performance than any single radiomics model using ADC (AUC 0.79, p = 0.007), FA (AUC 0.75, p = 0.001), or T1C (AUC 0.96, p = 0.678); the accuracy, sensitivity, and specificity of this model were 94.4%, 96.6%, and 92.0%, respectively. CONCLUSION Radiomics classifiers integrating multiparametric MRI parameters may be useful to differentiate the EGFR mutation status in brain metastases from lung cancer.

scholarly journals The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

2017 ◽  
Vol 07 (04) ◽  
pp. 117-129
Author(s):  
Xiaoshun Shi ◽  
Fuxi Huang ◽  
Allen M. Chen ◽  
Zhuolin Wu ◽  
Qianqian Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
The Impact

EGFR mutation status on brain metastases from non-small cell lung cancer

Lung Cancer ◽  
2016 ◽  
Vol 96 ◽  
pp. 101-107 ◽  
Author(s):  
Fred Hsu ◽  
Alex De Caluwe ◽  
David Anderson ◽  
Alan Nichol ◽  
Ted Toriumi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status

Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years.

1990 ◽  
Vol 8 (6) ◽  
pp. 1042-1049 ◽  
Author(s):  
M P Dearing ◽  
S M Steinberg ◽  
R Phelps ◽  
M J Anderson ◽  
J L Mulshine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cox Proportional Hazards ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage ◽  
The Impact

In a study of 411 patients with small-cell lung cancer (SCLC) entered on therapeutic clinical trials between 1973 and 1987, we analyzed whether changes in the prognostic importance of pretreatment factors had occurred during the 14-year time period. After adjusting for other prognostic factors, brain involvement was associated with shorter survival in patients treated before December 1979 (P = .024) but not in patients treated thereafter (P = .54). The patients diagnosed before 1979 had brain metastases documented by radionuclide scan while computed cranial tomography (CCT) was more commonly used after 1979. Patients who had brain metastases diagnosed by radionuclide scan lived a shorter period of time than patients who had the diagnosis made by the more sensitive CCT scan (P = .031). In contrast, Cox proportional hazards modeling showed that liver metastases in patients were associated with shorter survival in patients treated after 1979 (P = .0007) but not in patients treated before then (P = .30). A larger proportion of patients had a routine liver biopsy before 1979 than after 1979 when more patients had the liver staged with less sensitive imaging studies and biochemical parameters. Patients with SCLC whose cancer was confined to the thorax but had medical or anatomic contraindications to intensive chest radiotherapy had similar survival compared with patients with limited-stage SCLC who were treated with combination chemotherapy alone (P = .68). From these data we conclude: (1) the sensitivity of the staging procedures used can affect the impact on survival of cancer involvement of a given site; and (2) patients with cancer confined to their chest with medical or anatomic contraindications to chest radiotherapy do not have a shorter survival than patients with limited-stage disease treated with chemotherapy alone.

Sign in / Sign up

Export Citation Format

Share Document